PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för danuglipron. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

20 hits

Bibliografisk träff 2024-08-14

Design and Evaluation of 3-Phenyloxetane Derivative Agonists of the Glucagon-Like Peptide-1 Receptor.

Zhang Z, Pan H, Guo L, Cai C, Chen T, Zhang Z, Yang X, Zheng H, Jiang C, Wang Z, Yang Y, Wang Z, Zhang X, Zhang Y, Liu D.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.4c01177

Bibliografisk träff 2024-06-25

Pharmacodynamic and pharmacokinetic profiles of a novel GLP-1 receptor biased agonist-SAL0112.

Sun J, Xiao Y, Xing W, Jiang W, Hu X, Li H, Liu Z, Jin Q, Ren P, Zhang H, Lobie PE.

Biomed Pharmacother · journal article · DOI 10.1016/j.biopha.2024.116965

Bibliografisk träff 2024-06-10

Development of a sensitive LC-MS/MS assay to support human microdose study for an oral agonist of the GLP-1 receptor.

Kadar EP, Eng H, Kalgutkar AS, Holliman CL, Steeno GS.

Bioanalysis · research-article; journal article · DOI 10.1080/17576180.2024.2349421

Bibliografisk träff 2024-05-15

A novel approach to exploit Small-Molecule glucagon-like Peptide-1 receptor agonists with high potency.

Wang X, Yun Y, Chen L, Guo S, Niu B, Fang J, Yuan Q, Shen J, Xie X, Wang K.

Bioorg Med Chem · journal article · DOI 10.1016/j.bmc.2024.117761

Bibliografisk träff 2023-11-30

Newer pharmacological interventions directed at gut hormones for obesity.

Camilleri M, Acosta A.

Br J Pharmacol · research-article; review; journal article; research support, n.i.h., extramural · DOI 10.1111/bph.16278

Bibliografisk träff 2023-11-07

Evaluating Glycemic Control Efficacy and Safety of the Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron in Type 2 Diabetes Patients: A Systemic Review and Meta-Analysis.

Fatima H, Rangwala HS, Mustafa MS, Shafique MA, Abbas SR, Rizwan A, Fadlalla Ahmed TK, Arshad A.

Diabetes Metab Syndr Obes · review-article; review; journal article · DOI 10.2147/dmso.s439587

Bibliografisk träff 2023-11-02

Effect of Renal Impairment on the Pharmacokinetics of a Single Oral Dose of Danuglipron in Participants With Type 2 Diabetes.

Fediuk DJ, Gorman DN, Stoddard SA, Zhang Y, Ogden AG, Winton JA, Saxena AR.

J Clin Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1002/jcph.2371

Bibliografisk träff 2023-10-16

Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials.

Karakasis P, Patoulias D, Pamporis K, Stachteas P, Bougioukas KI, Klisic A, Fragakis N, Rizzo M.

Metabolism · meta-analysis; systematic review; journal article · DOI 10.1016/j.metabol.2023.155710

Bibliografisk träff 2023-08-15

6-Azaspiro[2.5]octanes as small molecule agonists of the human glucagon-like peptide-1 receptor.

Aspnes GE, Bagley SW, Coffey SB, Conn EL, Curto JM, Edmonds DJ, Genovino J, Griffith DA, Ingle G, Jiao W, Limberakis C, Mathiowetz AM, Piotrowski DW, Rose CR, Ruggeri RB, Wei L.

Bioorg Med Chem Lett · journal article · DOI 10.1016/j.bmcl.2023.129454

Bibliografisk träff 2023-06-13

Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: A 12-week, randomized, placebo-controlled, Phase 2 study comparing different dose-escalation schemes.

Saxena AR, Frias JP, Gorman DN, Lopez RN, Andrawis N, Tsamandouras N, Birnbaum MJ.

Diabetes Obes Metab · clinical trial, phase ii; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1111/dom.15168

Bibliografisk träff 2023-06-07

Discovery of Novel 5,6-Dihydro-1,2,4-triazine Derivatives as Efficacious Glucagon-Like Peptide-1 Receptor Agonists.

Chen L, Yun Y, Guo S, Wang X, Xiong M, Zhao T, Xu T, Shen J, Xie X, Wang K.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.3c00320

Bibliografisk träff 2023-05-01

Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes: A Randomized Clinical Trial.

Saxena AR, Frias JP, Brown LS, Gorman DN, Vasas S, Tsamandouras N, Birnbaum MJ.

JAMA Netw Open · research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.1001/jamanetworkopen.2023.14493

Bibliografisk träff 2022-12-19

A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of danuglipron (PF-06882961), an oral small-molecule glucagon-like peptide-1 receptor agonist, in Japanese adults with type 2 diabetes mellitus.

Ono R, Furihata K, Ichikawa Y, Nakazuru Y, Bergman A, Gorman DN, Saxena AR.

Diabetes Obes Metab · research support, non-u.s. gov't; research-article; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1111/dom.14928

Bibliografisk träff 2022-06-15

Investigating Potential GLP-1 Receptor Agonists in Cyclopeptides from Pseudostellaria heterophylla, Linum usitatissimum, and Drymaria diandra, and Peptides Derived from Heterophyllin B for the Treatment of Type 2 Diabetes: An In Silico Study.

Liao HJ, Tzen JTC.

Metabolites · research-article; journal article · DOI 10.3390/metabo12060549

Bibliografisk träff 2022-06-01

A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor.

Griffith DA, Edmonds DJ, Fortin JP, Kalgutkar AS, Kuzmiski JB, Loria PM, Saxena AR, Bagley SW, Buckeridge C, Curto JM, Derksen DR, Dias JM, Griffor MC, Han S, Jackson VM, Landis MS, Lettiere D, Limberakis C, Liu Y, Mathiowetz AM, Patel JC, Piotrowski DW, Price DA, Ruggeri RB, Tess DA.

J Med Chem · research support, non-u.s. gov't; research-article; journal article · DOI 10.1021/acs.jmedchem.1c01856

Bibliografisk träff 2021-06-14

Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial.

Saxena AR, Gorman DN, Esquejo RM, Bergman A, Chidsey K, Buckeridge C, Griffith DA, Kim AM.

Nat Med · research support, non-u.s. gov't; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1038/s41591-021-01391-w

Bibliografisk träff 2021-05-05

Evolving cryo-EM structural approaches for GPCR drug discovery.

Zhang X, Johnson RM, Drulyte I, Yu L, Kotecha A, Danev R, Wootten D, Sexton PM, Belousoff MJ.

Structure · research support, non-u.s. gov't; journal article · DOI 10.1016/j.str.2021.04.008

Bibliografisk träff 2021-02-24

Peptidyl and Non-Peptidyl Oral Glucagon-Like Peptide-1 Receptor Agonists.

Choe HJ, Cho YM.

Endocrinol Metab (Seoul) · review-article; review; journal article · DOI 10.3803/enm.2021.102

Bibliografisk träff 2020-10-06

Differential GLP-1R Binding and Activation by Peptide and Non-peptide Agonists.

Zhang X, Belousoff MJ, Zhao P, Kooistra AJ, Truong TT, Ang SY, Underwood CR, Egebjerg T, Šenel P, Stewart GD, Liang YL, Glukhova A, Venugopal H, Christopoulos A, Furness SGB, Miller LJ, Reedtz-Runge S, Langmead CJ, Gloriam DE, Danev R, Sexton PM, Wootten D.

Mol Cell · research support, non-u.s. gov't; journal article · DOI 10.1016/j.molcel.2020.09.020

Bibliografisk träff 2020-01-29

The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.

Romero FA, Jones CT, Xu Y, Fenaux M, Halcomb RL.

J Med Chem · review; journal article · DOI 10.1021/acs.jmedchem.9b01701